Portal de Periódicos da CAPES

High-Dose Busulfan and Seizures

1989; American College of Physicians; Volume: 111; Issue: 6 Linguagem: Inglês

10.7326/0003-4819-111-6-543_2

1539-3704

Anna Sureda,

Acute Myeloid Leukemia Research

Letters and Corrections15 September 1989High-Dose Busulfan and SeizuresA. Sureda, MD, J. Pérez de Oteyza, MD, J. García Laraña, MD, J. Odriozola, MD, PhDA. Sureda, MDSearch for more papers by this author, J. Pérez de Oteyza, MDSearch for more papers by this author, J. García Laraña, MDSearch for more papers by this author, J. Odriozola, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-6-543_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: High-dose bulsulfan and cyclophosphamide are currently used as a conditioning regimen for bone marrow transplantation in hematologic malignancies (1, 2) and in nonmalignant diseases (3). Although myelosupression, interstitial pulmonary fibrosis, gastrointestinal symptoms, and an Addison-like wasting syndrome are well-recognized side effects of busulfan (4), we know of only one case of myoclonic epilepsy associated to high-dose busulfan that has been reported (5). We report a patient who presented with generalized convulsions while receiving high-dose busulfan.An 18-year-old man with a Ph-positive acute lymphocytic leukemia in second remission was entered in an allogeneic bone marrow transplantation program with...References1. TutschkaCopelanKlein PEJ. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382-8. CrossrefMedlineGoogle Scholar2. CopelanGreverKapoorTutschka EMNP. Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukemia in accelerated or blastic phase. Br J Haematol. 1989;71:487-91. CrossrefMedlineGoogle Scholar3. BlazarRamsayKerseyKrivitArthurFilipovich BNJWDA. Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Transplantation. 1985;39:597-603. CrossrefMedlineGoogle Scholar4. LuBraineKaizerSaralTutschkaSantos CHHRPG. Preliminary results of high-dose bulsulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Res. 1984;68:711-7. Google Scholar5. MartellSherJacobsMonteagudo RCPF. High-dose busulfan and myoclonic epilepsy [Letter]. Ann Intern Med. 1987;107:173. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Hospital Ramón y Cajal Madrid Spain PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPersonalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines CommitteeRisk of Seizures in Children Receiving Busulphan-Containing Regimens for Stem Cell TransplantationHematopoietic Stem Cell Transplantation in Elderly Patients with Myelodisplastic Syndrome and Acute Myelogenous Leukemia: Use of Busulfan/Fludarabine for ConditioningBusulfan in Hematopoietic Stem Cell TransplantationOptimal Prevention of Seizures Induced by High-Dose BusulfanNeurologic complications of cancer therapyNon-endocrine late complications of bone marrow transplantation in childhood: part IThe role of busulfan in bone marrow transplantationLate complications after bone marrow transplantation in children and adolescentsAspects Concerning Busulfan Pharmacokinetics and BioavailabilityInfluence of prophylactic anticonvulsant therapy on high-dose busulphan kineticsPretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: Neurological and electroencephalographic prospective studyIn vivo distribution of [11C]-busulfan incynomolgus monkey and in the brain of a human patientAnticonvulsants and BusulfanWilliam E. Fitzsimmons, PharmD, MS, Richard Ghalie, MD, Herbert Kaizer, MD, PhDThe effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicityBusulphan and PhenytoinAndrew P. Grigg, MD, John D. Shepherd, MD, Gordon L. Phillips, MD 15 September 1989Volume 111, Issue 6Page: 543-544KeywordsBone marrow transplantationConvulsionsCyclophosphamideEpilepsyEpileptic seizuresHematologic malignanciesPrecursor cellsPulmonary fibrosis Issue Published: 15 September 1989 PDF downloadLoading ...